Financial reports
10-Q
2024 Q3
Quarterly report
14 Feb 24
10-Q
2024 Q2
Quarterly report
9 Nov 23
10-Q
2024 Q1
Quarterly report
10 Aug 23
10-K
2023 FY
Annual report
7 Jul 23
NT 10-K
Notice of late annual filing
30 Jun 23
10-Q
2023 Q3
Quarterly report
14 Feb 23
10-Q
2023 Q2
Quarterly report
1 Nov 22
10-Q
2023 Q1
Quarterly report
5 Aug 22
10-K
2022 FY
Annual report
22 Jun 22
10-Q
2022 Q3
Quarterly report
10 Feb 22
Current reports
8-K
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
5 Apr 24
8-K
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
27 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Oct 23
8-K
IGC Announces Results of its 2023 Annual Stockholders Meeting
21 Aug 23
8-K
IGC Pharma Secures $12 Million Line of Credit from O-Bank
7 Jul 23
8-K
IGC Pharma Announces a $3 Million Private Placement of its Common Stock
6 Jul 23
8-K
Departure of Directors or Certain Officers
5 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
21 Mar 23
Registration and prospectus
S-3
Shelf registration
17 Apr 24
424B5
Prospectus supplement for primary offering
21 Mar 24
424B5
Prospectus supplement for primary offering
31 Jan 24
S-3
Shelf registration
29 Dec 23
424B5
Prospectus supplement for primary offering
27 Oct 23
S-8
Registration of securities for employees
3 Oct 23
S-3
Shelf registration
29 Sep 23
S-8
Registration of securities for employees
23 Dec 21
POS AM
Prospectus update (post-effective amendment)
22 Jan 21
424B5
Prospectus supplement for primary offering
13 Jan 21
Proxies
DEF 14A
Definitive proxy
26 Jul 23
DEF 14A
Definitive proxy
25 Jul 22
DEF 14A
Definitive proxy
15 Sep 21
DEFA14A
Additional proxy soliciting materials
21 Dec 20
DEF 14A
Definitive proxy
8 Dec 20
DEF 14A
Definitive proxy
13 Dec 19
DEF 14A
Definitive proxy
5 Jul 18
DEF 14A
Definitive proxy
10 Oct 17
PRE 14A
Preliminary proxy
15 Sep 17
PRE 14A
Preliminary proxy
8 Mar 17
Other
EFFECT
Notice of effectiveness
9 Jan 24
CORRESP
Correspondence with SEC
4 Jan 24
UPLOAD
Letter from SEC
4 Jan 24
EFFECT
Notice of effectiveness
6 Oct 23
CORRESP
Correspondence with SEC
4 Oct 23
UPLOAD
Letter from SEC
3 Oct 23
EFFECT
Notice of effectiveness
1 Feb 21
EFFECT
Notice of effectiveness
5 Jan 21
UPLOAD
Letter from SEC
31 Dec 20
CORRESP
Correspondence with SEC
31 Dec 20
Ownership